Clincosm LogoSign in Get a demo

The Role of Genetic Factors in the Development of Epilepsy in the Kazakh Population

Sponsor
Asfendiyarov Kazakh National Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05088499
Collaborator
(none)
600
Enrollment
1
Location
10.6
Anticipated Duration (Months)
56.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a GWAS study that aims to identify possible candidate genes associate to epilepsy by exploring single nucleotide polymorphism (SNP) in a group of epilepsy, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with epilepsy

Condition or Disease Intervention/Treatment Phase
  • Genetic: DNA analysis

Detailed Description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Preventive and Personalized Medicine (2021-2023)
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Dec 20, 2022
Anticipated Study Completion Date :
Dec 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental group:

Patients with epilepsy

Genetic: DNA analysis
GWAS
Control group

Patients without epilepsy

Genetic: DNA analysis
GWAS

Outcome Measures

Primary Outcome Measures

  1. number of SNPs associated with epilepsy [1 year]

    Using GWAS to identify candidate genes associate with epilepsy

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 5 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

  • Children with seizures, confirmed by EEG and no morphological damage to the brain, confirmed by MRI of the brain;

  • The age of the patients is from 0 to 5 years;

  • Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;

  • Children are parents or legal guardians who have given written informed consent.

Exclusion Criteria:

  • Children over 5 years old;

  • Children whose parents, according to the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;

  • Children with seizures with brain damage that cause epilepsy;

  • Children of a non-Kazakh ethnic group.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Altynshash Jaxybayeva Almaty Kazakhstan

Sponsors and Collaborators

  • Asfendiyarov Kazakh National Medical University

Investigators

  • Study Director: Altynshash Jaxybayeva, Astana Medical University, Nur-Sultan, Kazakhstan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ildar Fakhradiyev, Head of the Laboratory of Experimental Medicine, Asfendiyarov Kazakh National Medical University
ClinicalTrials.gov Identifier:
NCT05088499
Other Study ID Numbers:
  • 1199
First Posted:
Oct 22, 2021
Last Update Posted:
May 18, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ildar Fakhradiyev, Head of the Laboratory of Experimental Medicine, Asfendiyarov Kazakh National Medical University
GWAS
Additional relevant MeSH terms:
Epilepsy

Study Results

No Results Posted as of May 18, 2022